1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Breast Cancer and the Environment Research Program (BCERP) is sponsored by National Institutes of Health (NIH). The BCERP supports integrated scientific research to enhance the understanding of environmental and genetic factors underlying breast cancer risk.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Breast Cancer and the Environment Research Program | EGRP/DCCPS/NCI/NIH Breast Cancer and the Environment Research Program The Breast Cancer and the Environment Research Program (BCERP) was a joint effort co-funded by the National Institute of Environmental Health Sciences (NIEHS) and the National Cancer Institute (NCI). BCERP began with the Breast Cancer and the Environment Research Centers (BCERC) in 2003.
BCERP supported a multidisciplinary network of scientists, clinicians, and community partners to examine the effects of environmental exposures that may predispose a woman to breast cancer throughout her life. BCERP-funded projects incorporated a transdisciplinary approach, involving collaborations between different scientific disciplines to address a common research question.
Each BCERP project was comprised of a biology study, a human study, and a community engagement component. This broadened research focus added to the growing knowledge of environmental and genetic factors that may influence breast cancer risk across the lifespan and reflects recommendations made by the Interagency Breast Cancer and Environmental Research Coordinating Committee (IBCERCC) in 2013.
Learn more about the BCERP BCERP published more than 150 scientific manuscripts. View a list of BCERP publications . Additionally, the BCERP community partners have developed a wide range of outreach and educational materials related to normal breast development and how exposure to chemicals that act like hormones in the body during specific developmental periods might influence breast cancer susceptibility.
View BCERP education and outreach materials . Breast Cancer and the Environment: Controversial and Emerging Exposures Workshop Summary - May 14, 2021 Next Phase of BCERP Announced – 10/8/2015 Press release announcing the 7-year awards – 10/14/2003 For basic science questions: For cancer epidemiology questions: Gary L. Ellison, PhD, MPH For basic science questions: Neeraja Sathamoorthy, PhD Last Updated: 05 Aug, 2025
According to the current listing, eligibility includes: Not specified in detail, but generally open to research institutions. Confirm the full requirements in the official notice before applying.
Breast Cancer and the Environment Research Program (BCERP) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article